Cargando…
Why Do ACG and AGA Guidelines Differ for the Use of Probiotics and the Prevention of CDI?
Autores principales: | McFarland, Lynne V., Kullar, Ravina, Johnson, Stuart, Sniffen, Jason C., Woolard, Kristin, Goldstein, Ellie J.C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8893126/ https://www.ncbi.nlm.nih.gov/pubmed/35020606 http://dx.doi.org/10.14309/ajg.0000000000001567 |
Ejemplares similares
-
Why 2 Studies That Used the Same Probiotic May Have Come Up With Different Outcomes
por: McFarland, Lynne V, et al.
Publicado: (2021) -
Lactobacillus Bacteremia and Probiotics: A Review
por: Kullar, Ravina, et al.
Publicado: (2023) -
Potential Roles for Probiotics in the Treatment of COVID-19 Patients and Prevention of Complications Associated with Increased Antibiotic Use
por: Kullar, Ravina, et al.
Publicado: (2021) -
Investigational Treatment Agents for Recurrent Clostridioides difficile Infection (rCDI)
por: Kullar, Ravina, et al.
Publicado: (2020) -
Choosing an appropriate probiotic product for your patient: An evidence-based practical guide
por: Sniffen, Jason C., et al.
Publicado: (2018)